Status
Conditions
Treatments
About
The purpose of this Open Label Safety Study is to provide access to and evaluate the safety and tolerability of TPV/r in treatment-experienced patients with advanced HIV-1 infection who have failed at least two PI-containing regimens, and have limited treatment options.
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Hypersensitivity to active ingredients or any of the excipients in tipranavir or ritonavir
Required use of restricted medications.
Female patients of childbearing potential who have a positive pregnancy test at baseline or are breast feeding.
Any medical condition which in the opinion of the investigator would interfere with the patients' ability to participate in or adhere to the requirements of this protocol.
Use of other investigational drugs, within 30 days prior to TPV boosted with ritonavir initiation and for the duration of study participation
Hepatic impairment evidenced by the following baseline laboratory findings:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal